Roja MM, Sánchez CCD, Ruelas GZE, Pulido DN, Godínez AL

Language: Spanish
References: 10
Page: 310-313
PDF size: 141.55 Kb.

ABSTRACT

Introduction: psoriatic arthritis (PA) is the most frequent comorbidity in psoriasis. There are multiple risk factors, the most important are: obesity, severity of psoriasis, nail pitting, time of evolution, among others. The objective of this study was to determine the risk factors associated with the development of PA in Mexican patients with psoriasis.
Material and methods: case-control, retrospective, cross-sectional study, conducted at La Raza National Medical Center, in patients with psoriasis from 2017-2021. Clinical records of patients with and without psoriatic arthritis, and without autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis), with more than two years of evolution with psoriasis, and without biological treatment before the diagnosis of PA were included. For the comparison between groups, chisquare and student t test were used. Variables with p ‹0.2 were included in the multiple logistic regression analysis to determine risk factors. The study was approved by the Ethics and Research Committee.
Results: 123 patients were included, all with obesity and 34 (27.6%) had psoriatic arthritis. The significant risk factors for the development of psoriatic arthritis were: nail disease (pitting) (OR 8.019; 95% CI: 2.5-25.6) and disease severity, pasi ›5.
Conclusions: the most important risk factors in our study were nail disease and severity of psoriasis with a pasi ›5. Obesity was not significant, despite being reported as one of the main risk factors in the literature.

REFERENCES

1. Veale DJ y Fearon U, The pathogenesis of psoriatic arthritis, Lancet 2018; 391(10136):2273-84.

2. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC,Jullien D et al., Prevalence of psoriatic arthritis in patientswith psoriasis: a systematic review and meta-analysis of observationaland clinical studies, J Am Acad Dermatol 2019;80(1):251-65.e19.

3. Cañete JA, Pinto Tasende F, Rebollo Laserna J, Gómez CastroS y Queiro RJD, The impact of comorbidity on patient-reportedoutcomes in psoriatic arthritis: a systematic literature review,Rheumatol Ther 2020; 7(2):237-57.

4. Belinchón I, Salgado-Boquete L, López-Ferrer A, Ferran M, Coto-Segura P, Rivera R et al., Dermatologists’ role in the earlydiagnosis of psoriatic arthritis: expert recommendations, ActasDermo-Sifiliograficas 2020; 111(10):835-46.

5. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, BehrensF et al., Prevalence of rheumatologist-diagnosed psoriaticarthritis in patients with psoriasis in European/North Americandermatology clinics, J Am Acad Dermatol 2013; 69(5):729-35.

6. Scher JU, Ogdie A, Merola JF y Ritchlin C, Preventing psoriaticarthritis: focusing on patients with psoriasis at increased risk oftransition, Nat Rev Rheumatol 2019; 15(3):153-66.

7. Soltani-Arabshahi R, Wong B, Feng B-J, Goldgar DE, Duffin KCy Krueger GG, Obesity in early adulthood as a risk factor forpsoriatic arthritis, Arch Dermatol 2010; 146(7):721-6.

8. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE y KremersHM, Incidence and clinical predictors of psoriatic arthritisin patients with psoriasis: a population-based study, ArthritisRheum 2009; 61:233-9.

9. Li W, Han J y Qureshi A, Obesity and risk incident psoriatic arthritisin US women, Ann Rheum Dis 2012; 71(8):1267-72.

10. Eder L, Law T, Chandran V, Shanmugarajah S, Shen H, Rosen CFet al., Association between environmental factors and onset ofpsoriatic arthritis in patients with psoriasis, Arthritis Care Res(Nueva Jersey) 2011; 63(8):1091-7.